Empty AAV capsids over 2% trigger TLR9-mediated inflammation and gene therapy-associated uveitis, but this risk is mitigated by the AAVX platform with advanced purification and perioperative steroids validated in LUXTURNA trials [254,255]. This evidence concerns the gene TLR9 and uveitis.